Sara Sampietro/LinkedIn
Nov 26, 2025, 10:32
Sara Sampietro Introduces The New HemosIL Chromogenic Factor IX
Sara Sampietro, Product Manager – EEMEA at Werfen, shared on LinkedIn:
”Last week in Nyborg, Denmark, I had the privilege to discuss the role of the laboratory in the management of patients with Hemophilia and introduce our latest release: the NEW HemosIL Chromogenic Factor IX.
A big thanks to our partner ILS and to everyone who joined the conversation and contributed to driving progress in Hemostasis care.
Together, we can continue to make a difference!”
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia